Home › Type 1 Diabetes › NCT05268250

Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Who can join

Ages 8 to 65 · All sexes

Inclusion Criteria:

* child age between 8-12 years, physician confirmed T1D diagnosis,
* either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points,
* child is on an intensive insulin regimen (pump or MDI).

Exclusion Criteria:

* children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points,
* children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease),
* children and parents who do not speak English.

About the study

This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.

What is being tested

• R2D2 mHealth intervention (behavioral)

Sponsor: Nemours Children's Clinic · Participants: 180 · Started: Feb 26, 2024

Contact the study team

• Susana R Patton, PhD · Phone: 9046972000

Official record on ClinicalTrials.gov — NCT05268250

Locations in the U.S.

Conditions

• Type 1 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.